Market Assessment, Oncology Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker Driven Prescribing in Oncology Physician & Payer Forum EU5 2014 Report

As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available for several oncology indications, including breast cancer, colorectal cancer, and non-small-cell lung cancer, and many more such therapies are in the pipeline. Biomarkers enable the selection of patient populations likely to respond to a particular therapy and thus limit treatment costs by preventing a therapy’s uptake among patients unlikely to respond to treatment. As a result, hospital and clinician funds can be allocated more efficiently. The drug labels that restrict treatment to biomarker-positive patients also allow tighter control of spending, especially in the cost-conscious EU5 countries.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician & Payer Forum | EU5 | 2014

Related Market Assessment Reports

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Detailed, Expanded Analysis (US)

Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Detailed, Expanded Analysis (US)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

Dry And Wet Age-Related Macular Degeneration – Geographic Focus-China – Dry And Wet Age-Related Macular Degeneration – China In-Depth (China)